High circulating IGF-1 concentrations have been associated with cancer risk [43], recently supported by Mendelian randomisation studies, particularly for breast, colorectal and prostate cancer [44–47], while no significant associations were observed for ovarian cancer [45], and no corresponding evidence is available for pancreatic cancer. Here, IGF1 is linked to prostate cancer.